Analysis: Lamictal highlights increased class action scrutiny in pharma cases

The US Court of Appeals for the Third Circuit on 22 April vacated class certification in a lawsuit alleging that GlaxoSmithKline and Teva suppressed generic competition to Lamictal, an anticonvulsant used to treat epilepsy and bipolar disorder. White & Case partner Michael Hamburger, senior associate Adam Acosta and associate Gina Chiappetta analyse how the appellate court’s decision fits into a broader trend of courts clamping down on class certification in pharmaceutical cases.